Windtree therapeutics, inc. expanded access policy

Expanded access is a process regulated by the U.S. Food and Drug Administration (FDA) which allows pharmaceutical companies to provide investigational products to patients with serious, life-threatening diseases or conditions and who cannot participate in a clinical study.
Windtree is not currently offering expanded access to our investigational products. However, Windtree will periodically review its expanded access policy. For additional information about this policy, please contact ex[email protected] Responses will be provided within approximately five (5) business days.

Get more information on FDA Expanded Access programs here (link leaves the Windtree website)